8
Jan
2026
Following the Science to Immunology: Kate Haviland on The Long Run
Kate Haviland is today’s guest on The Long Run. Kate is the former CEO of Cambridge, Mass.-based Blueprint Medicines. Blueprint was one of the big biotech success stories of 2025. The company was acquired by Sanofi for $9.1 billion in cash at closing, and potentially $9.5 billion if certain milestones are met. The company started out with a vision for... Read More
7
Jan
2026
Biotech Needs Its Own David Sacks
One question from 2025 has consistently frustrated me: Why did AI and crypto become top strategic priorities in the first year of the Trump Administration while biotech was largely ignored? Trump’s core issues over the last decade have been immigration, trade, energy dominance, border security, China, and re-shoring of US manufacturing. It was not obvious that “Artificial Intelligence” and “digital... Read More
6
Jan
2026
Timmerman Traverse for Damon Runyon Hits $1M Goal, Striving Toward Kilimanjaro
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has done it again. We have exceeded our team goal of raising $1 million for brilliant young cancer researchers around the US. We currently stand at $1,094,672. This team isn’t done. The latest group of 22 biotech executives and investors have one month left before traveling to Tanzania, banding together in common... Read More
6
Jan
2026
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Dec
2025
The Next Alzheimer’s Treatments May Spur the Brain to Protect Itself
The Alzheimer’s research community has tried for decades to get rid of amyloid plaques in the brain, in hopes of slowing down or preventing the memory-robbing disease. But amyloid might not be an insurmountable enemy after all. A remarkable group of people whose ability to resist the cognitive decline of Alzheimer’s was, until recently, completely invisible. These were individuals who... Read More
18
Dec
2025
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
15
Dec
2025
Biotech’s Future Will Be More Distributed
When we started our first biotech company, MediChem Life Sciences in the early 1990s in Chicago, there was nothing resembling a “biotech ecosystem” nearby. We had to build our own labs, figure out how to raise money and how to recruit a team of scientists and professionals. The universities in the Chicago area were more focused on basic science. The... Read More
11
Dec
2025
5AM, OrbiMed Join $70M Bet on Prolynx Long-Lasting GLP-1 Weight Loss Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Dec
2025
To Improve Health, Design for Agency
Agency — the conviction I can shape my future — is a vital driver of human health and human potential. It is also the factor overlooked by most digital health platforms. University of Pennsylvania psychologist Martin Seligman, who has spent decades studying this, says agency boils down to the belief “I can make a positive difference in the world.” People... Read More
10
Dec
2025
PsiThera Gets $47.5M To Make Small Molecules Against TNF Superfamily
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2025
FDA Turmoil Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Nov
2025
A New Book on GLP-1’s Contested Scientific Roots and Complex Cultural Impact — Plus Further Reading
In this weekend’s Wall Street Journal, I review Off the Scales, a fascinating new book by Reuters journalist Aimee Donnellan about the discovery and development of GLP-1 agonists and their impact on medicine, culture, and society. The review, aimed at a generalist audience, focuses mostly on the societal and cultural implications, but TR readers may be especially interested in the... Read More
25
Nov
2025
London Life Sciences Week Shows UK Biotech is Open and Thriving
London has always been multicultural, multidisciplinary, and in constant motion. It is a global mosaic where academia, entrepreneurship, finance, policy, and creative arts intersect with ease. That character was evident during London Life Sciences Week, which has grown far beyond its origins around the Jefferies London Healthcare Conference. What began as a finance event has become something broader and more... Read More
24
Nov
2025
Recommended Podcasts (and A Few Books), 2025 Year-End Edition
It’s time for my annual feature: recommended podcasts (and a few books) for TR readers to consider. As usual, these suggestions generally steer clear of politics; they also aren’t the only podcasts I listen to, but they’re the ones I’m least likely to skip. Biotech and Health Care Of course, everyone in biotech should listen to Luke’s interview series, The... Read More
22
Nov
2025
Why Patients – And Many Innovative Doctors – Are Pursuing Health Outside the System
Our current system of delivering care is awful from the perspective of seemingly every stakeholder. It frustrates, enrages, saddens, and depletes patients and physicians alike. No one designed it this way. It evolved through a series of choices and contingencies that perhaps made sense at the time but now seem to have led us down an evolutionary dead end. While... Read More
20
Nov
2025
Merck Buys Cidara, Abbott Acquires Exact, & Function Flies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Building a Rare Disease Company: Neil Kumar on The Long Run
Neil Kumar is today’s guest on The Long Run. Neil is the founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma. BridgeBio got started a little more than 10 years ago with an idea of creating what it calls a “hub and spoke” business model for rare disease drug development. The hope was to find opportunities that were biologically compelling,... Read More
17
Nov
2025
The Dark Side of the GLP-1 Weight Loss Drugs: Eating Disorders
There has been much fanfare about the acquisition by Pfizer of Metsera, the developer of injectable and oral GLP-1 agonists and other peptides for the treatment of obesity. The $10 billion price tag, the bidding war with Novo Nordisk, the lawsuits, it all made for high drama. It was a moment of vindication for biotechs that have struggled for years... Read More
17
Nov
2025
Seattle’s AI-Biotech Leaders See Hype, Hope, and Hard Problems
AI is reshaping the foundations of biotechnology, but progress isn’t uniform. While some breakthroughs such as generative protein design models and AI-based target identification are transforming drug discovery, others are overhyped or held back by stubborn infrastructure and data barriers. At last month’s AI Leadership Summit in Seattle, co-hosted by Life Science Washington and Madrona, a group of founders, CEOs,... Read More